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Cypate-octreote peptide analogue conjugate (Cytate) was investigated as a prostate cancer receptortargeted contrast agent. The absorption and fluorescence spectra of Cytate were ranged in the nearinfrared “tissue optical window.” Time-resolved investigation of polarization-dependent fluorescence
emitted from Cytate in solution as well as in cancerous and normal prostate tissues was conducted.
Polarization preservation characteristics of Cytate in solution and tissues were studied. Fluorescence
intensity emitted from the Cytate-stained cancerous prostate tissue was found to be much stronger than
that from the Cytate-stained normal prostate tissue, indicating more Cytate uptake in the former tissue type. The polarization anisotropy of Cytate contained in cancerous prostate tissue was found to be
larger than that in the normal prostate tissue, indicating a larger degree of polarization preservation in
Cytate-stained cancerous tissue. The temporal profiles of fluorescence from Cytate solution and from
Cytate-stained prostate tissue were fitted using a time-dependent fluorescence depolarization model.
The photoluminescence imaging of Cytate-stained cancerous and normal prostate tissues was accomplished, showing the potential of Cytate as a fluorescence marker for prostate cancer detection.
© 2008 Optical Society of America
OCIS codes:
300.6280, 110.3080.

1. Introduction

Prostate cancer was projected to account for ∼29% of
all cancer incidences in men, exceeding lung and
bronchus cancer in the US, and to cause more than
27000 deaths in 2007 [1]. Currently prostate cancer
diagnosis is based on digital rectal examination
(DRE), blood prostate specific antigen (PSA) test,
and the trans-rectal ultrasound (TRUS) imaging
0003-6935/08/132281-09$15.00/0
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[2]. While TRUS is no longer considered as a firstline screening test for prostate cancer because of its
poor spatial resolution and contrast [3], DRE has a
reported sensitivity of as low as 18%–22% in asymptomatic men [2]. PSA has limited specificity, and the
reported positive predictive value of PSA in asymptomatic men is 28%–35% [2]. The confirmation of
prostate cancer requires a needle biopsy of the prostate. In the biopsy, a number of cores of prostate tissue are taken out with a thin needle guided into
selectedregions of the prostate with an ultrasound
probe. Because of poor spatial resolution and limited
1 May 2008 / Vol. 47, No. 13 / APPLIED OPTICS

2281

accuracy of these currently available methods, and
the invasive nature of needle biopsy, there is a need
to develop a noninvasive technique for early detection of prostate cancer with higher accuracy and
resolution.
Fluorescence spectroscopy was used as a novel tool
for detection of cancer by Alfano and his group [4] in
the 1980s. The work was extended to differentiate
human malignant breast tissues from benign and
normal tissue types using UV excitation [5]. Further
work on breast tissues and atherosclerotic arteries
showed how time-resolved fluorescence could provide
information not available from steady state spectral
analysis alone [6]. Several groups have investigated
various promising approaches using optical spectroscopy [7] and imaging [8] with high sensitivity and
spatial resolution [3,7–10]. Since conventional steady state fluorescence measurements are performed
by integrating fluorescence over a longer time in
comparison with the lifetime of the fluorescence, the
resulting data do not include information of the dynamics of the emission process and the effect of depolarization on fluorescence due to scattering in
tissues. Some of these issues may be addressed by
performing time-resolved fluorescence depolarization measurements, which measure the intensity
profile and degree of polarization of fluorescence
within its lifetime, and provide information complementary to that obtained from steady state spectral
measurements [11].
The use of intrinsic chromophores to differentiate
the optical properties of diseased and healthy human
tissues is limited by their ultraviolet emission bands
[12], which are far from the near-infrared (NIR)
“tissue optical window” [13]. Over the past decade,
Indocyanine Green (ICG, also called Cardio Green),
a clinically approved NIR dye by the US Food and
Drug Administration (FDA), has been investigated
as a contrast agent for optical detection of tumors
[14]. ICG fluoresces in the range of 775 nm to 850 nm,
which avoids the absorption bands at 950 nm and
1195 nm due to water, which is the main chromophore component in human tissue in the NIR range
[15,16]. However, ICG is not designed to specifically
target cancer cells. The investigations of receptor expression in normal and cancer tissues suggest that
small peptide-dye conjugates can be used to target
over-expressed receptors on tumors to enhance specificity [17]. Biological studies have indicated that
somatostatin receptors (SSTRs), which have five subtypes, are over-expressed in human prostate tumor
[18]. It was reported that each subtype of somatostatin receptors could be identified on the basis of
molecular modeling of its corresponding peptide conjugate [19]. The previous investigation showed that
a small ICG-derivative dye-peptide, cypate-octreote
peptide analogue conjugate (Cytate), could be used
for effectively targeting somatostatin receptor-rich
tumor in the animal model because of the high affinity of Cytate for the somatostatin receptors [20].
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In this paper, we report time-resolved fluorescence
and NIR imaging studies for Cytate, an optical contrast agent for human prostate cancer detection. The
absorption and fluorescence spectra of Cytate were
measured in the wavelength regions from 650 nm
to 900 nm and 1100 nm, respectively. Time-resolved
fluorescence polarization measurements were performed on Cytate solution and Cytate-stained cancerous and normal prostate tissues. Fluorescence
imaging of two small pieces of Cytate-stained normal
and cancerous prostate tissues (one for each) sandwiched between large pieces of normal prostate tissues was accomplished.
The experimental data obtained from a Cytate solution were fitted using a time-dependent fluorescence depolarization model [21,22]. The resultant
parameters from Cytate fluorescence in solution and
in prostate tissue were compared for understanding the effect of the rotational degree of freedom of
Cytate in a tissue medium. An empirical model
was applied to describe the time-resolved fluorescence kinetics and polarization anisotropy of Cytate
in human prostate tissue. The differences of fluorescence and image intensities between Cytate-stained
cancerous and normal prostate tissues showed preferential uptake of Cytate in the former tissue type.
2. Tumor-Targeted Mechanism of Cytate and Its
Absorption and Fluorescence Spectra

Cytate used in this study was prepared by Achilefu’s
group at the Washington University School of Medicine. The molecular structure of Cytate is shown in
Fig. 1. It is mainly composed of ICG and the somatostatin receptor ligand, which delivers the ICG to
the receptors presented in the tumor [20]. The synthesis of this contrast agent was reported elsewhere
[20]. The advantages of this receptor-targeted peptide-dye contrast agent include enhancing localization in tumors, rapid clearance from the nontarget
(normal) tissue, possibility of preparing a library of
peptides for rapid identification of bioactive molecules [20], and keeping the spectral advantages in

Fig. 1. Molecular structure of the cypate-octreote peptide analogue conjugate (Cytate). The part enclosed by a dashed box is ICG
(nonspecific dye without a SSTR ligand). R indicates the molecule
chain of a SSTR ligand.

the NIR “tissue optical window.” It was reported that
the small ICG-derivative dye-peptide, Cytate, preferentially localized for over 24 hours in tumor with
over-expressed somatostatin receptors in an animal
model [20].
The human prostate is a highly hormone-sensitive
organ. Numerous studies have found that somatostatin is directly or indirectly responsible in the regulation of prostate function [23]. Somatostatin is a small
cyclic peptide. In addition to playing an important
regulatory role of hormones, this peptide controls
cell proliferation in cancerous tissues [18]. Therefore,
tumors arising from somatostatin-needed tissues
frequently express a high density of somatostatin receptors [24]. Somatostatin receptors are known for
predominant expression in several human adenomas
such as somatotroph and lactotroph adenomas, and
neuroendocrine tumor including human prostate
cancer [18,24,25], and can be used as a basis for
in vivo tumor targeting. Several control experiments
were carried out to determine whether expression of
somatostatin receptors is up regulated in human
prostate malignant cells [26]. Among them, Hansson
et al. have found, by using fluorescing-labeled SSTR
octreotide-binding probes by immunochemical analysis, that SSTR2 and SSTR4 are over-expressed in human prostate cancerous cells [26]. And Bugaj et al.
have shown that the ligand of Cytate (ICG-derivative
dye-peptide, cypate-octreote peptide analogue conjugate) to target somatostatin receptors in animal
model is octreotide [20]. The combination of molecular probes and optical imaging methods has the potential to provide a better cancer detection technique
with high sensitivity and specificity. The successful
detection of Cytate in somatostatin receptors overexpressed in tumors in an animal model [20] motivated us to use Cytate to target the over-expressed
specific SSTR2 and SSTR4 in human prostate
cancerous cells. The basis of using Cytate as a prostate cancer contrast agent depends on two factors:
(1) the high affinity of octreotide (ligand of Cytate)
for the somatostatin receptors [20], and (2) the
over-expression of SSTR2 and SSTR4 in human prostate cancer cells [26].
In our spectral study, Cytate was solvated in 20%
aqueous dimethyl sulfoxide (DMSO). The absorption
spectrum of Cytate in DMSO solution was measured
using a Perkin-Elmer Lambda 9 UV/VIS/NIR spectrophotometer in the spectral range of 300 nm to
900 nm. The fluorescence spectrum of Cytate was
measured using a far-red to NIR spectral setup excited by a 680 nm diode laser. Fluorescence emission
from the sample was focused on the entrance slit of a
SPEX Minimate 0:25 m monochromator (spectrometer) and detected by a Hamamatsu P394A PbS detector mounted at the exit slit of the monochromator.
Signals from the detector were recorded by a PAR
model HR-8 lock-in amplifier connected to a computer [27].
Figures 2(a) and 2(b) show the measured absorption and fluorescence emission spectra of Cytate,

Fig. 2. (a) Absorption and (b) fluorescence spectra of Cytate in
20% aqueous DMSO. The fluorescence was obtained with an excitation of a 680 nm diode laser beam.

respectively. The absorption band of Cytate ranges
from 680 nm to 830 nm with a shoulder peak at
∼720 nm and a strong peak at 789 nm. The fluorescence spectrum covers from 800 nm to 950 nm with a
main peak at 837 nm and a weak peak at 913 nm.
The results show that Cytate possesses the spectral
advantages of ICG, i.e., the fluorescence and the absorption ranges are in the NIR range of the “tissue
optical window” [27].
3. Experimental Methods for Time-Resolved and
Imaging Measurements

The experimental arrangement for the time-resolved
fluorescence measurements is described in our previous work [10]. Pulses of 130 fs duration at 800 nm
from a Coherent Mira 900 mode-locked Ti:sapphire
laser at a repetition rate of 82 MHz were used
to pump the samples (Cytate solution and Cytatestained cancerous or normal prostate tissues). The
fluorescence emission was collected by a large diameter lens with a focal length of 5 cm and directed
onto the slit of a synchroscan streak camera with
a temporal resolution of 10 ps. A long pass filter
and an 800 nm notch filter were used to cut off the
excitation wavelength. Two polarizers, P1 and P2 ,
were used as a polarizer and an analyzer, respectively. The polarization direction of P2 was varied
1 May 2008 / Vol. 47, No. 13 / APPLIED OPTICS
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from 0° to 90° with respect to that of P1 to record the
fluorescence intensity profiles of parallel and perpendicular polarization components of the fluorescence.
The temporal profiles recorded by a silicon intensified target (SIT) of the streak camera were analyzed
to obtain temporal and polarization information [10].
The Cytate solution used for time-resolved fluorescence study was prepared by adding Cytate into 20%
aqueous dimethyl sulfoxide (DMSO). Six cancerous
and six normal prostate tissue samples from six different patients obtained from the National Disease
Research Interchange (NDRI) and the Cooperation
Human Tissue Network (CHTN) were used for the
time-resolved fluorescence and optical imaging measurements under the Institutional Review Board
(IRB) approval at City College of New York (CCNY).
Each cancerous tissue had a corresponding normal tissue sample from the same patient used for
the control experiment. Samples were neither chemically treated nor frozen prior to the experiments.
Cancerous and normal prostate tissues used for
the time-resolved fluorescence measurements were
cut into ∼2 cm × ∼1 cm × ∼0:5 cm (length × width ×
thickness) pieces. For each prostate tissue sample,
measurements were performed at six different locations to get an average value. The cancerous and normal prostate tissue samples were soaked in the same
Cytate-DMSO (20% aqueous dimethyl sulfoxide) solution with a Cytate concentration of ∼3:2 × 10−6 M
for fifteen minutes. Then the samples were put into
sodium phosphate buffer (Sigma-Aldrich) to wash
off the unbound Cytate. All the sample preparations and measurements were performed at room
temperature.
The schematic diagram of the NIR optical imaging
setup is shown in Fig. 3. A laser beam at 637 nm was
used to illuminate the sample. A wide-bandpass
filter at 800 nm with a FWHM of 40 nm was placed
in front of a CCD camera to record images formed by
light emitted from the sample. A bandpass filter was
used to block the excitation wavelength and to collect

Fig. 3. Schematic diagram of the optical spectral imaging setup.
The structure of a Cytate-stained cancerous-and-normal prostate
tissue sample covered by a large piece of normal prostate tissue is
shown schematically in the sample position.
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only the light emitted from the sample. The spatial
resolution of the CCD camera is 20 μm=pixel [10].
The prostate tissue samples used for the imaging
measurements consisted of a small piece of cancerous
prostate tissue and a small piece of normal prostate
tissue. They were first soaked in the same CytateDMSO (20% aqueous dimethyl sulfoxide) solution
with a Cytate concentration of ∼3:2 × 10−6 M for fifteen minutes, and then put into sodium phosphate
buffer to wash off the unbound Cytate. The stained
normal and cancerous prostate tissues were covered
by a large piece of normal prostate tissue as shown in
the sample position of Fig. 3.
4.

Experimental Results and Discussion

A. Time-Resolved Fluorescence Polarization Anisotropy of
Cytate in 20% Aqueous DMSO

The measured temporal profiles of the fluorescence
emitted from Cytate in DMSO solution for two polarization directions, parallel and perpendicular to
the polarization of the excitation at 800 nm, are
shown in Fig. 4(a). The thick- and thin-curve profiles represent the parallel ½I ‖ ðtÞ and perpendicular
½I ⊥ ðtÞ components, respectively. The time-dependent
polarization anisotropy can be calculated using the
following equation [21,22]:
rðtÞ ¼

I ‖ ðtÞ − I ⊥ ðtÞ
:
I ‖ ðtÞ þ 2I ⊥ ðtÞ

ð1Þ

The thin curve in Fig. 4(b) displays the time evolution of rðtÞ as calculated. The decay behavior of rðtÞ
reflects the dipole reorientation of Cytate in solvent
since the degree of polarization of the fluorescence
depends on the rotation time and fluorescence lifetime of the molecules [21,22]. If molecular rotation
is much faster compared to the florescence lifetime,
the emitting molecules become randomly oriented
very quickly, resulting in depolarized emission. If
molecules rotate much more slowly in comparison
with the fluorescence decay time, then the emission
remains strongly polarized. Polarization anisotropy
found in our case suggests that rotation time is of
the same order as fluorescence lifetime.
In Fig. 4(a), the main differences between parallel
and perpendicular components are the following:
(1) The intensity of I ‖ is greater than that of I ⊥ for
all decay times. The peak intensity of the parallel
component I ‖ ð0Þ is almost three times stronger than
that of the perpendicular component I ⊥ ð0Þ. This indicates the polarization preservation nature of Cytate. (2) There is a distinct difference between the
decay slopes of the two components, which can be
seen clearly by normalizing the peak of the perpendicular component to that of the parallel component,
as shown by the thin-dashed curve in Fig. 4(a). Since
the rotation time and fluorescence lifetime of Cytate
are on same time scale in our case, the overall decay
time is affected by both reorientation of molecules
and fluorescence decay kinetics. Since the parallel

where rð0Þ is anisotropy at t ¼ 0 and τrot is the rotation time of the fluorophore molecule in solvent, determined by the diffusion coefficient, the solvent
viscosity, and the molecular radius [21,22]. The value
of rð0Þ depends on the angle between the absorption
and emission dipoles, and the expectation value of
the second order Legendre polynomial for the distribution function of dipoles [10,28]. The maximum theoretical value of rð0Þ is 0.4 [10,21,22,28].
The experimental value of rð0Þ obtained from the
data shown in Fig. 4(b) is ∼0:33, which is in reasonable agreement with the theoretical value of 0.4
[21,22]. As mentioned by Flemming [21] and Porter
[22], the measured value of rð0Þ is always smaller
than its theoretical value due to (1) the rapid internal
motions of the macromolecules, since the macromolecules must contain a flexible substructure that
can undergo rapid depolarization rotation, (2) scattering of light in tissues, and (3) birefringence of
the quartz cell containing the samples. This result
indicates that the transition dipole moments of Cytate molecules in solution are randomly oriented,
and the depolarization effects of Cytate in 20% aqueous DMSO solvent can be confined to molecular
rotations and to the trivial effect of initial randomness [21]. The polarization anisotropy peak value,
rð0Þ, and the rotation time,τrot , of Cytate in solution
can be obtained by fitting the experimental data of
rðtÞ shown in Fig. 4(b) using Eq. (2). The best fit
was obtained with the parameter values of rð0Þ ¼
0:337  0:032 and τrot ¼ 352  21 ps, and the fitting
curve is shown by the thick-dark curve in Fig. 4(b).

Fig. 4. Temporal polarization profiles and polarization anisotropy of light emitted from Cytate in 20% aqueous DMSO with a polarized 800 nm laser illumination. (a) Profiles of the time-resolved
fluorescence components having polarization directions parallel
(thick curve) and perpendicular (thin curve) to the polarization direction of the exciting light. The thin-dashed curve displays the
normalized perpendicular components. (b) Time-dependent polarization anisotropy (thin curve) calculated using the measured data
shown in (a) and Eq. (1) shown in the text, and the fitting curve
(thick curve) calculated using Eq. (2) shown in the text and the
data shown by the thin curve in Fig. 5(b).

and perpendicular components emitted from Cytate
have same fluorescence lifetime, the fast decay of the
parallel component and slow decay of the perpendicular component are caused by the Cytate molecular
rotation.
In this simple model where Cytate molecules in solution are considered to undergo Brownian rotation
as Einstein spheres, the time-resolved fluorescence
kinetics and polarization anisotropy from Cytate in
aquatic DMSO can be shown as [21,22]

rðtÞ ¼ rð0Þ exp −

t
τrot


;

ð2Þ

B. Time-Resolved Fluorescence Polarization Anisotropy
of Cytate Contained in Stained Cancerous and Normal
Prostate Tissues

Six Cytate-stained cancerous and six Cytate-stained
normal prostate tissue samples from six patients
were used for the time-resolved fluorescence measurements. For each sample, measurements were
performed on six or more different locations for statistical analysis. Before the measurements were performed, the tissue sample was carefully checked to
determine the hard parts to locate the small region
of the cancerous tissue. This is acknowledged to be a
simple way to find the location of malignancy [29].
Two typical time-resolved fluorescence intensity
profiles for the cancerous and normal prostate tissue samples stained with Cytate are displayed in
Fig. 5(a). The thick-solid and thick-dashed curve profiles represent the parallel and the perpendicular
components of emission from stained cancerous tissue, respectively. The thin-solid and thin-dashed
curve profiles display the parallel and perpendicular
components of emission from stained normal tissue,
respectively.
One of the most important features of the profiles in Fig. 5(a) is the higher emission intensity
of the stained cancerous tissue compared to the
stained normal tissue throughout the Cytate emission range. Using the data in Fig. 5(a), for the
1 May 2008 / Vol. 47, No. 13 / APPLIED OPTICS
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Fig. 5. (a) Time-resolved fluorescence intensity of light emitted
from Cytate-stained cancerous and normal prostate tissues with
800 nm laser illumination. The thick-solid and thick-dashed curve
profiles are the parallel and perpendicular components emitted
from Cytate-stained cancerous prostate tissue, respectively. The
thin-solid and thin-dashed curve profiles display the parallel
and perpendicular components emitted from Cytate-stained normal prostate tissues, respectively. (b) Time-dependent polarization
anisotropy calculated using Eq. (1) shown in the text and the measured data shown in Fig. 5(a). The thin-solid and thin-dashed
curve profiles indicate the rðtÞ for Cytate-stained cancerous and
normal prostate tissues, respectively. The fitting curves for Cytate
in cancerous prostate tissue (thick-solid curve) and Cytate in normal prostate tissue (thin-solid curve) were calculated using Eq. (3)
shown in the text and the corresponding polarization anisotropy
shown in Fig. 5(b).

parallel polarization configuration, the ratio of peak
fluorescence intensity of the Cytate-stained cancerous tissue to that of the normal tissues was found
to be ∼3:57, while for the perpendicular configuration, the ratio was ∼3:25. These ratios indicate that
cancerous prostate tissue has higher Cytate intake
than normal tissue.
Another important feature of the temporal profiles
is that I ‖ is greater than I ⊥ throughout the decay
period for both cancerous and normal tissues. At
2286
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the peak position, I cancer
ð0Þ is ∼1:60 times stronger
‖
cancer
ð0Þ, and the ratio of I normal
ð0Þ to
than I ⊥
‖
normal
I⊥
ð0Þ is ∼1:46. This indicates that the fluorescence emitted from both Cytate-stained cancerous
and normal prostate tissues show the polarization preservation property, although the ratio of
I ‖ ð0Þ=I ⊥ ð0Þ is smaller than that of Cytate solution.
Using Eq. (1) and the measured values of I ‖ ðtÞ and
I ⊥ ðtÞ shown in Fig. 5(a), the temporal profiles of
the polarization anisotropy rðtÞ from Cytate in
stained cancerous (thin-solid curve) and normal
(thin-dashed curve) prostate tissues were calculated,
and the results are displayed in Fig. 5(b).
The interesting features of rðtÞ curves shown in
Fig. 5(b) are the following: (1) the profiles of Cytatestained tissue show a flatter decay compared to that
of Cytate solution; and (2) the values of the polarization anisotropy of Cytate in the stained cancerous tissue are always larger than that of the stained normal
tissue. The peak intensity values of rð0Þ for cancerous and normal tissues were found to be rð0Þcancer ¼
0:167  0:021 and rð0Þnormal ¼ 0:133  0:011, presented as mean values  standard deviations. These
results indicate that the Cytate-stained cancerous
tissue shows a better polarization preservation property than the Cytate-stained normal prostate tissue.
The polarization preservation properties of Cytatestained prostate tissue can be used to enhance the
image contrast between cancerous and normal prostate tissue areas combining with a fluorescencepolarization-difference imaging (FPDI) technique
[10,27,30].
The value of rð0Þ for a dye solution depends on the
viscosity of the solvent [28]. Above a critical value of
the viscosity of about 3000 poise, a normalized orientation distribution function was used as a model for
fluorescent molecules instead of random distribution
[28]. By applying this distribution function, a value of
rð0Þ ¼ 0:1039 was calculated for the condition of the
viscosity greater than 3000 poise [10,28]. It was also
reported that biological living tissue might mimic the
behavior of viscous liquids [31]. The viscosities of
biological tissues, including prostate tissue, were reported to be much higher than 3000 poise [32]. If the
case of Cytate in prostate tissue is considered as a
fluorescent dye in a “very high viscosity liquid,”
the anisotropy rð0Þ should be expected to be in the
range between ∼0:10 and ∼0:12.
The physical model generated from our previous
study [10] on cybesin (another NIR contrast agent
used to target bombesin receptor that is also overexpressed in prostate tumors) suggests that the
time-resolved fluorescence polarization anisotropy
rðtÞ of the emission from NIR fluorescent dye contained in stained human prostate tissues can be
considered to have two components: (1) a static anisotropy component caused by the emission from
the tissue cell-bonded Cytate molecules without rotation; and (2) a time-dependent anisotropy component
formed by the emission from the unbound Cytate

molecules with rotation in the body fluid of prostate
tissue [10]. These assumptions are reasonable because a tissue cell is too massive to rotate compared
to a Cytate molecule. This empirical model was developed to describe the time-resolved fluorescence kinetics and polarization anisotropy emitted from
contrast agent stained tissues [10]. Using this model,
the temporal fluorescence polarization anisotropy
rðtÞ of Cytate contained in stained prostate tissues
can be described by


t
rðtÞ ¼ r1 þ r0 exp 
;
ð3Þ
τrot
where r0 expð−t=τrot Þ is the time-dependent portion of
the polarization anisotropy induced by the “free”
Cytate molecules in the fluid of prostate tissue, τrot
is the rotation time of the “free” Cytate in prostate
tissue, rð0Þ is the peak value of the polarization anisotropy of the “free” Cytate molecules, and r1 is the
static portion of the polarization anisotropy induced
by the cell-bond Cytate molecules in prostate tissue.
The three parameters τrot , r0 , and r1 can be obtained
by fitting the experimental data of rðtÞ shown in
Fig. 5(b) using Eq. (3).
The best fitting curves for Cytate-stained cancerous (thick-solid curve) and normal (thin-solid curve)
prostate tissues are shown in Fig. 5(b). The fitting
results yielded the following parameters: r0 ¼
0:115  0:012, τrot ¼ 900  180 ps, and r1 ¼ 0:062
0:013 for Cytate in stained cancerous prostate tissue,
and r0 ¼ 0:109  0:030, τrot ¼ 550  140 ps, and r1 ¼
0:014  0:004 for Cytate in stained normal tissue.
These values are in reasonable agreement with
our experimental data.
The fitting results yield that rcancer
> rnormal
. This
1
1
can be understood from the fact that the perpendicular component of the fluorescence emitted from cellbond Cytate molecules is mainly contributed by the
photons undergoing multiple scattering [10,30].
Since the excitation wavelength of 800 nm is close
to the strong absorption peak of Cytate and cancerous prostate tissue has higher Cytate intake than
normal tissue, the stained cancerous tissue region
would absorb more photons than the stained normal
tissue regions. Light from the same excitation source
would go deeper in normal prostate tissue than in
cancerous tissue. As a result, the fluorescence from
normal prostate tissue comes from the Cytate molecules embedded in deeper tissue layers than the Cytate molecules in the cancerous prostate tissue [10].
The light emitted from the stained cancerous tissue
area undergoes less multiple scattering than that
from the stained normal tissue. As a result, the degree of polarization and the value of r1 for the stained
cancerous tissue region are much larger than that of
the stained normal tissue region [10].
The fitting results also show that τcancer
> τnormal
.
rot
rot
The larger decay time of free Cytate molecules in
cancerous prostate tissue indicates the higher local
viscosity of cancerous prostate tissue due to high
density and decreasing interstitial spacing between

cells. The higher density of cancerous cells can be recognized by the nature of evolution of a malignant
tumor [29]. First the tumor grows in volume; when
it reaches some kind of confining volume, the mechanical pressure increases its cell density. When the
tumor cell density exceeds a certain compaction maximum, invasion starts [29,33]. The tumor grading
system for prostate cancer includes the well known
five Gleason grades, usually denoted as stages 1–5
[34]. The pattern of Gleason grade 1 (corresponding
to early stage) consists of a circumscribed mass of
evenly placed uniform glands. With grade advances,
the cancer cells proliferate and begin to merge into
an “island” [34]. This pattern appears at grade 3
and is obvious at grade 5 [34]. The microscopic histological images shown in our previous work [27] also
indicate the “island” structure and high density of
cancerous cell. The higher cell density in cancerous
prostate tissue [29,33,34] gives the molecules less
“free” rotation space [10,29,34]. In addition, the
dye crowds more in cancerous tissue due to higher
adsorption levels of bound Cytate as shown by the
larger emission intensity in Fig. 5(a). The crowding
dye chains form a compact or contracted coil in which
the dye is embedded [35]. This effect increases the
local viscosity [35], which in our view is the reason
behind the larger decay time of Cytate in cancerous
prostate tissue compared to that in normal prostate
tissue samples.
5.

Optical Imaging

To study the potential of Cytate for prostate cancer
detection by NIR imaging, cancerous-and-normal
prostate tissue samples were imaged using a NIR
spectral imaging system. In order to image a hidden
tissue, a small piece of cancerous prostate tissue and
another small piece of normal prostate tissue stained
with Cytate were sandwiched between two large
pieces of prostate normal tissue with a thickness
of ∼1 mm for the front piece. The fluorescence images
of the Cytate-stained prostate tissues were recorded
at 800 nm by exciting at 637 nm. Figure 6(a) shows
recorded NIR images of the stained cancerous and
normal prostate tissues embedded underneath the
∼1 mm thick normal prostate tissues. As displayed
in Fig. 6(a), the emission intensity of the Cytatestained cancerous tissue is higher than that of the
Cytate-stained normal tissue.
This property of preferential uptake of Cytate by
cancerous prostate tissue can be more clearly visualized by Fig. 6(b), which is the digital spatial cross
section of intensity distribution of the image shown
in Fig. 6(a). Using the digital data shown in Fig. 6(b),
the ratio of imaging intensity of the cancerous tissue
area to that of normal tissue area is found to be
∼3:54. To compare the results of the imaging measurements with that of time-resolved fluorescence
experiments, peak intensities of I ‖ and I ⊥ for both
cancerous and normal tissue shown in Fig. 5(a) were
added, and the ratio of peak fluorescence intensities
emitted from Cytate-stained cancerous tissue to that
1 May 2008 / Vol. 47, No. 13 / APPLIED OPTICS
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over-expressed specific SSTR2 and SSTR4 in human
prostate cancerous cells.
6.

Conclusion

Steady state absorption- and fluorescence-spectral
measurements were performed on Cytate, a cancer
receptor-targeted contrast agent, to study its viability in cancer detection. Time-resolved fluorescence
kinetics and polarization anisotropy of Cytate in solution and in stained human cancerous and normal
prostate tissues were investigated. The experimental
results show a larger degree of polarization preservation of fluorescence from Cytate in the stained
cancerous tissue than in the stained normal tissue.
The fluorescence intensity emitted from the Cytatestained cancerous prostate tissue was found to be
much stronger than that from the Cytate-stained
normal prostate tissue indicating that cancerous
prostate tissue has a higher Cytate intake than normal tissue. The time-resolved fluorescence intensity
profile from a Cytate solution was fitted using a timedependent fluorescence depolarization model. An
empirical physical model was applied to describe the
behavior of fluorescence kinetics and polarization anisotropy of Cytate in stained cancerous and normal
prostate tissues. Optical imaging of cancerous and
normal prostate tissues stained with Cytate was performed. The fluorescence image of the Cytate-stained
cancerous prostate tissue region was found to be
much brighter than that of the Cytate-stained normal tissue region. Cytate was shown to be an excellent contrast agent because its absorption and
fluorescence spectra lie in the NIR “tissue optical
window.” Both fluorescence intensity and optical
imaging studies show the potential of Cytate as a
fluorescent marker in prostate cancer detection.
7.
Fig. 6. (a) Contrast agent fluorescence image of a cancerous-andnormal prostate tissue sample (a tiny piece of Cytate-stained cancerous prostate tissue and a tiny piece of Cytate-stained normal
prostate tissue covered by a large piece of normal prostate tissue).
(b) Digital spatial cross section intensity distribution of the image
shown in Fig. 6(a) at a row crossing the areas of the stained cancer
(C) and normal (N) tissues.

from the normal tissue was calculated to be ∼3:45.
This value obtained from the time-resolved fluorescence measurements is in a good agreement
with that obtained from the spectral imaging
measurements.
Both fluorescence intensity measurements and optical spectral imaging study show the preferential
uptake of Cytate by prostate cancerous tissue. Since
Hansson et al. reported that the over-expressed
SSTR2 and SSTR4 on prostate tumor cells bind octreotide [26], and the ligand of Cytate to target somatostatin receptors in animal model is octreotide [20],
we may infer that Cytate achieved targeting the
2288
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Future Work

Further biomedical studies are needed to follow up
this spectral and optical imaging investigation. Some
immunochemical analysis is needed to identify the
somatostatin receptor subtypes that are targeted
by Cytate. Experiments for quantifying the difference in the number of somatostatin receptors between cancerous and normal prostate tissues need
to be performed and compared for different Gleason
grades. Some biomedical work is needed to study the
transport of Cytate across the cell membrane and
into the cell cytoplasm, and to see whether 20%
DMSO concentration of aqueous solution has any adverse effect on tissue.
This research is supported by U.S. Army Medical
Research and Material Command under grant
DAMD17-01-1-0084 (CUNY RF 47462-00-01). The
authors acknowledge the help of NDRI and CHTN
for providing normal and cancerous prostate tissue
samples for the measurements, the valuable discussion with G. C. Tang at IUSL and C. J. Gu at Molecular Virology Division of Columbia University
Medical Center, and the help of M. Sharanov at IUSL
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